Clinical Trial Update: Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing adjunctive risperidone to placebo for major depressive disorder not responding to standard therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Risperdal (risperidone)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED